Whether the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy is a reliable strategy to preserve ovarian function is controversial owing to both the lack of data on long-term ovarian function and pregnancies and the safety concerns about the potential negative interactions between endocrine therapy and chemotherapy.
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial / Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., Giordano, M., Garrone, O., Levaggi, A., Poggio, F., Giraudi, S., Bighin, C., Vecchio, C., Sertoli, M.R., Pronzato, P., Del Mastro, L., DE LAURENTIIS, M.. - In: JAMA. - ISSN 0098-7484. - 314:24(2015), pp. 2632-40-2640. [10.1001/jama.2015.17291]
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial
DE LAURENTIIS, MICHELINO
2015
Abstract
Whether the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy is a reliable strategy to preserve ovarian function is controversial owing to both the lack of data on long-term ovarian function and pregnancies and the safety concerns about the potential negative interactions between endocrine therapy and chemotherapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
joi150154.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
428.67 kB
Formato
Adobe PDF
|
428.67 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
